News Releases
by Year
2016
Dec. 26, 2016 (PDF/112KB) Licensing
Sumitomo Dainippon Pharma to Conduct Meropenem Business in Five Countries of South-East Asia and Hong Kong
Dec. 22, 2016 (PDF/153KB) Licensing
Sunovion Enters into License Agreement for Three Approved Treatment Options for People with COPD in the U.S.
Dec. 21, 2016 (PDF/153KB) Corporate
Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
Dec. 21, 2016 (PDF/98KB) Corporate
Sumitomo Dainippon Pharma Announces Merger of US consolidated subsidiaries
Nov. 11, 2016 (PDF/119KB) Corporate
Sumitomo Dainippon Pharma announces Organizational Realignment and Changes Related to Officers and Other Key Positions
Nov. 04, 2016 (PDF/95KB) R&D
Sumitomo Dainippon Pharma announces the data of an investigational WT1 cancer peptide vaccine, DSP-7888 will be presented at the ASH 2016
Oct. 27, 2016 (PDF/562KB) Finances
Supplementary Financial Data for the Second Quarter of the Year Ending March 31, 2017
Oct. 27, 2016 (PDF/297KB) Finances
Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2017 [Japanese GAAP] (Unaudited)
Oct. 27, 2016 (PDF/77KB) Corporate
Sumitomo Dainippon Pharma Announces the Establishment of a Subsidiary for Promotion of Authorized Generics and others
Oct. 24, 2016 (PDF/84KB) Corporate
Sumitomo Dainippon Pharma's U.S. Subsidiary Sunovion Pharmaceuticals Completes Acquisition of Cynapsus Therapeutics Inc. (Canadian Specialty Central Nervous System Biotechnology Company)
Oct. 21, 2016 (PDF/239KB) Finances
Sumitomo Dainippon Pharma Announces Revisions to Its Financial Forecasts for the Half-Year Ended September 30, 2016
Oct. 21, 2016 (PDF/112KB) Corporate
Sumitomo Dainippon Pharma Announces the Results of Its Early Retirement Program Offer for Japanese Employees
Oct. 13, 2016 (PDF/322KB) R&D
Sunovion Announces FDA Filing Acceptance of New Drug Application for SUN-101/eFlow for the Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD)
Oct. 06, 2016 (PDF/146KB) R&D
Sumitomo Dainippon Pharma announces the final data analysis of a global phase 3 study of an investigational anti-cancer drug Napabucasin (CO.23 study) will be presented at the ESMO 2016 Congress
Sep. 20, 2016 (PDF/188KB) R&D
Sunovion Announces Results from Pivotal Study Evaluating Novel Drug Candidate Dasotraline in Children with ADHD
Sep. 01, 2016 (PDF/102KB) Corporate
Sumitomo Dainippon Pharma's U.S. Subsidiary Sunovion to Acquire Cynapsus Therapeutics Inc. (Canadian Specialty Central Nervous System Biotechnology Company)
Aug. 30, 2016 (PDF/132KB) Corporate
Sumitomo Dainippon Pharma announces offering an Early Retirement Program to Japanese Employees and Reduction in Executive Remuneration
Jul. 29, 2016 (PDF/316KB) R&D
Sunovion Submits New Drug Application for SUN-101/eFlow to the FDA for the Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD)
Jul. 27, 2016 (PDF/537KB) Finances
Supplementary Financial Data for the First Quarter of the Year Ending March 31, 2017
Jul. 27, 2016 (PDF/283KB) Finances
Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2017 [Japanese GAAP] (Unaudited)
Jul. 26, 2016 (PDF/76KB) R&D
Sysmex, Healios and Sumitomo Dainippon Pharma Begin Joint R&D Related to Pre-Transplant Immune Reaction Testing Method for Retinal Pigment Epithelial Cells (RPE Cells) Derived from Allogeneic iPS Cells
Jul. 25, 2016 (PDF/131KB) Sustainability
Sumitomo Dainippon Pharma Listed in FTSE4Good Index Series of Socially Responsible Investment for the 14th Consecutive Year
May 19, 2016 (PDF/58KB) R&D
Sumitomo Dainippon Pharma announces Clinical Data of Investigational anti-cancer drugs Napabucasin and Amcasertib in Multiple Cancer Types at ASCO 2016
May 11, 2016 (PDF/548KB) Finances
Supplementary Financial Data for the Year Ended March 31, 2016
May 11, 2016 (PDF/969KB) Finances
Summary of Consolidated Financial Results for the Year Ended March 31, 2016 [Japanese GAAP] (Unaudited)
May 11, 2016 (PDF/115KB) Corporate
Sumitomo Dainippon Pharma announces Change of Directors
Apr. 27, 2016 (PDF/316KB) R&D
Sunovion Pharmaceuticals Inc. Announces Positive Results from Two Phase 3 Clinical Studies Evaluating SUN-101/eFlow (glycopyrrolate) in People with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Apr. 19, 2016 (PDF/44KB) Sustainability
Sumitomo Dainippon Pharma Contributes to Kumamoto Earthquake Relief Efforts in Japan
Apr. 11, 2016 (PDF/115KB) R&D
Kyoto University and Sumitomo Dainippon Pharma Launch Second Stage of Joint Research Project for Innovative Oncology Therapeutics (DSK Project)
Mar. 01, 2016 (PDF/103KB) Corporate
Sumitomo Dainippon Pharma announces Organizational Realignment and Changes Related to Officers and Other Key Positions
Jan. 27, 2016 (PDF/549KB) Finances
Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2016
Jan. 27, 2016 (PDF/330KB) Finances
Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2016 [Japanese GAAP] (Unaudited)
Jan. 25, 2016 (PDF/57KB) R&D
Boston Biomedical’s Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured at the ASCO 2016 Gastrointestinal Cancers Symposium
Jan. 25, 2016 (PDF/229KB) R&D
Sunovion Announces Results from a Study Evaluating the Abuse Potential of Investigational Drug Dasotraline